Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis

Abstract

Background:

Daclizumab is a monoclonal antibody that binds the high-affinity interleukin-2 receptor and was approved for the treatment of relapsing multiple sclerosis. Due to severe inflammatory brain disorders, the approval was suspended in March 2018.

Objective and Methods:

This retrospective cohort study summarizes clinical, laboratory, radiological, and histological findings of seven patients who developed meningo-/encephalitis after daclizumab therapy.

Results:

Patients presented with encephalitis and/or meningitis and suffered from systemic symptoms such as fever (5/7), exanthema (5/7), or gastrointestinal symptoms (4/7). Secondary autoimmune diseases developed. Blood analysis revealed an increase in eosinophils (5/7). Six patients fulfilled the diagnostic criteria for a drug reaction with eosinophilia and systemic symptoms (DRESS). Magnetic resonance imaging (MRI) showed multiple contrast-enhancing lesions, and enhancement of the ependyma (6/7), meninges (5/7), cranial or spinal nerves (2/7), and a vasculitic pattern (3/7). Histology revealed a pronounced inflammatory infiltrate consisting of lymphocytes, plasma cells and eosinophils, and densely infiltrated vessels. Most patients showed an insufficient therapeutic response and a high disability at last follow-up (median Expanded Disability Status Scale (EDSS) 8). Two patients died.

Conclusion:

Meningoencephalitis and DRESS may occur with daclizumab therapy. This potential lethal side effect is characterized by a dysregulated immune response. Our findings underline the importance of postmarketing drug surveillance.

Keywords

Daclizumab multiple sclerosis regulatory T cells autoimmune diseases meningoencephalitis natural killer cells

Get full access to this article

View all access options for this article.

References

Kappos

Wiendl

Selmaj

, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2015; 373(15): 1418–1428.

Bielekova

Catalfamo

Reichert-Scrivner

, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103: 5941–5946.

Blevins

Griffith

, et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol 2009; 66(4): 471–479.

Fontenot

Rasmussen

Gavin

, et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells (vol. 6, p. 1142, 2005). Nat Immunol 2006; 7: 427.

Chinen

Kannan

Levine

, et al. An essential role for the IL-2 receptor in T-reg cell function. Nat Immunol 2016; 17: 1322–1333.

Ohayon

Richert

, et al. CNS vasculitis in a patient with MS on daclizumab monotherapy. Neurology 2013; 80(5): 453–457.

Scheibe

Metz

Radbruch

, et al. Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS. Neurol Neuroimmunol Neuroinflamm 2018; 5(5): e479.

Rauer

Stork

Urbach

, et al. Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy. Neurology 2018; 91: e359–e363.

Luessi

Engel

Spreer

, et al. GFAPalpha IgG-associated encephalitis upon daclizumab treatment of MS. Neurol Neuroimmunol Neuroinflamm 2018; 5(5): e481.

10.

Devlin

Swayne

Newman

, et al. A case of immune-mediated encephalitis related to daclizumab therapy. Mult Scler 2019; 25: 750–753.

11.

Wynn

Kaufman

Montalban

, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9(4): 381–390.

12.

Kuruvilla

Khan

DA.

Eosinophilic drug allergy. Clin Rev Allergy Immunol 2016; 50(2): 228–239.

13.

Gaha

Landry

Belair

, et al. DRESS syndrome: Cerebral vasculitic-like presentation. Neuroradiology 2015; 57(10): 1015–1021.

14.

Gambineri

Torgerson

Ochs

HD.

Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003; 15(4): 430–435.

15.

Barzaghi

Passerini

Bacchetta

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: A paradigm of immunodeficiency with autoimmunity. Front Immunol 2012; 3: 211.

16.

Chen

Chung

Chiou

, et al. Quantitative analysis of tissue inflammation and responses to treatment in immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome, and review of literature. J Microbiol Immunol Infect 2016; 49(5): 775–782.

17.

de Serre

NPM

Canioni

Ganousse

, et al. Digestive histopathological presentation of IPEX syndrome. Mod Pathol 2009; 22(1): 95–102.

18.

Mottershead

Neuberger

Daclizumab. Expert Opin Biol Ther 2007; 7: 1583–1596.

19.

Patel

DD.

Escape from tolerance in the human X-linked autoimmunity-allergic disregulation syndrome and the Scurfy mouse. J Clin Invest 2001; 107(2): 155–157.

20.

Giovannoni

Kappos

Gold

, et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord 2016; 9: 36–46.

21.

Ghiringhelli

Larmonier

Schmitt

, et al. CD4(+)CD25(+) regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34(2): 336–344.